Download PDF
TumorDiagnostik & Therapie 2015; 36(07): 411-415
DOI: 10.1055/s-0035-1553893
Thieme Onkologie aktuell
© Georg Thieme Verlag KG Stuttgart · New York

An immunohistochemical investigation of the expression of somatostatin receptor subtypes – should therapeutic trials be performed to determine the efficacy of somatostatin analogs in treating advanced thyroid malignances?

H. Pisarek
1   Department of Neuroendocrinology, Chair of Laboratory Medicine, Medical University of Lodz, Poland
,
M. Pawlikowski
2   Department of Immunoendocrinology, Chair of Endocrinology, Medical University of Lodz, Poland
,
M. Marchlewska
3   Department of General and Endocrinological Surgery, Copernicus Memorial Hospital, Lodz, Poland
,
R. Minias
4   Department of Pathomorphology and Clinical Cytopathology, Interfaculty Chair of Pathomorphology, Medical University of Lodz, Poland
,
K. Winczyk
1   Department of Neuroendocrinology, Chair of Laboratory Medicine, Medical University of Lodz, Poland
› Author Affiliations
Further Information

Publication History





Publication Date:
29 October 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Somatostatin and its analogs through the specific receptor are known to demonstrate antiproliferative, anti-angiogenic and pro-apoptotic actions. The presence of SSTR-1–5 has not been sufficiently explored in poorly differentiated and undifferentiated thyroid tumors. The aim was to investigate the SSTR subtypes expression in these aggressive thyroid tumors. The study also discusses the usefulness of SSTR analogs as an alternative to conventional forms of therapy.

Methods: The analysis was performed by immunohistochemistry on the 14 archived poorly differentiated and 4 anaplastic thyroid carcinomas. A group of benign thyroid pathologies consisting of 11 patients was also included.

Results: SSTR-1, 2A, 2B, 3 and 5 were found to be expressed both in benign and malignant thyroid diseases, while SSTR-4 was not. Expression of SSTR-1 and SSTR-5 was found in samples with poorly differentiated thyroid tumors with a score of at least 2.0 being recorded in 10 tumors (71.4 %). For SSTR-2A the same or higher score was noted in 5/14 (35.7 %), for SSTR-2B in 4/14 (28.6 %) and for SSTR-3 in 3/14 (21.4 %) samples. SSTR-1, 2B and 5 were found to have a score of at least 2.0 in all undifferentiated thyroid tumors. Immunostaining of SSTR-2A and 3 was observed in 50 % of samples. The immunopositive reactions were observed both in the membranes and cytoplasm of the thyroid cancer’ cells. In some cases positive immunostaining was localized also in the endothelium of intrathyroidal blood vessels.

Conclusions: The somatostatin multiligand analogs or selective agonists could be considered alternatives to conventional therapeutic agents in aggressive thyroid tumors.

Key words

aggressive thyroid carcinomas - somatostatin receptor subtypes - treatment modality
 

  • References

  • 1 Chiacchio S, Lorenzoni A, Boni G et al. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol 2008; 33: 341-357
    PubMedGoogle Scholar
  • 2 Smallridge RC, Ain KB, Asa SL et al. American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid 2012; 22: 1104-1139
    CrossrefPubMedGoogle Scholar
  • 3 Sugitani I, Miyauchi A, Sugino K et al. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 2012; 36: 1247-1254
    CrossrefPubMedGoogle Scholar
  • 4 Taccaliti A, Silvetti F, Palmonella G et al. Anaplastic thyroid carcinoma. Front Endocrinol 2012; 3: 84
    PubMedGoogle Scholar
  • 5 Kloos RT, Ringel MD, Knopp MV et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27: 1675-1684
    CrossrefPubMedGoogle Scholar
  • 6 Krajewska J, Olczyk T, Roskosz J et al. Treatment with sorafenib in advanced thyroid cancer – a case report. Pol J Endocrinol 2010; 61: 492-496
    PubMedGoogle Scholar
  • 7 Criel M, Geurs F. Remarkable Effect of Metronomic Chemotherapy in Diffuse Lung Metastases of Thyroid Cancer. J Thyroid Disord Ther 2012; 1: 101
    PubMedGoogle Scholar
  • 8 Cabanillas ME, Sherman SI. Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma. Endocr Relat Cancer 2012; 19: C19-C22
    CrossrefPubMedGoogle Scholar
  • 9 Prichard CN, Kim S, Yazici YD et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 2007; 117: 674-679
    CrossrefPubMedGoogle Scholar
  • 10 Mooney CJ, Nagaiah G, Fu P et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009; 19: 233-240
    CrossrefPubMedGoogle Scholar
  • 11 Pei XH, Xiong Y. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 2005; 24: 2787-2795
    CrossrefPubMedGoogle Scholar
  • 12 Weng JR, Chen CY, Pinzone JJ et al. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 2006; 13: 401-413
    CrossrefPubMedGoogle Scholar
  • 13 Antico-Arciuch VG, Russo MA, Dima M et al. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2011; 2: 1109-1126
    CrossrefPubMedGoogle Scholar
  • 14 Pawlikowski M, Kunert-Radek J, Stępień H. Somatostatin – an antiproliferative hormone. In: Progress in Neuropeptide Research. Dohler KD, Pawlikowski M. (eds.) Birkhauser Verlag; Basel: 1989: 3-12
    CrossrefGoogle Scholar
  • 15 Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008; 13: 822-840
    CrossrefPubMedGoogle Scholar
  • 16 Voltering EA. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm 2003; 18: 601-609
    CrossrefPubMedGoogle Scholar
  • 17 Hu C, Yi C, Hao Z. The effect of somatostatin and SSTR 3 on proliferation and apoptosis of gastric cancer cells. Cancer Biol Ther 2004; 3: 726-730
    CrossrefPubMedGoogle Scholar
  • 18 Theodoropoulou M, Stalla GK. Somatostatin receptors: From signaling to clinical practice. Front Neuroendocrinol 2013; 34: 228-252
    CrossrefPubMedGoogle Scholar
  • 19 Cozzi R, Montin M, Attanasio R et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006; 91: 1397-1403
    CrossrefPubMedGoogle Scholar
  • 20 Farrall AJ, Ruffin M, Wetli-Hermosillo K et al. Long-term treatment of acromegaly with pasireotide (SOM230): results from a phase II extension study. Endocr Rev 2010; 31 (Suppl. 01) S856 (abst OR16-5)
    PubMedGoogle Scholar
  • 21 Colao A, Petersenn S, Newell-Price J et al. 12-month phase 3 study of pasireotide in Cushing’s disease. N Eng J Med 2012; 366: 914-924
    CrossrefPubMedGoogle Scholar
  • 22 Rinke A, Muller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663
    CrossrefPubMedGoogle Scholar
  • 23 Mato E, Matias-Guiu X, Chico A et al. Somatostatin and Somatostatin Receptor Subtype Gene Expression in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 1998; 83: 2417-2420
    CrossrefPubMedGoogle Scholar
  • 24 Zatelli MC, Piccin D, Tagliati F et al. Selective Activation of Somatostatin Receptor Subtypes Differentially Modulates Secretion and Viability in Human Medullary Thyroid Carcinoma Primary Cultures: Potential Clinical Perspectives. J Clin Endocrinol Metab 2006; 91: 2218-2224
    CrossrefPubMedGoogle Scholar
  • 25 Pawlikowski M. Somatostatin Receptors in Human Tumors – In Vitro Studies. In Somatostatin Analogs in Diagnostics and Therapy. Edited by Pawlikowski Marek. Landes Bioscience; 2007: 39-46
    Google Scholar
  • 26 Pisarek H, Stępień T, Kubiak R et al. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res 2009; 2: 1
    CrossrefPubMedGoogle Scholar
  • 27 Klagge A, Krause K, Schierle K et al. Somatostatin receptor subtype expression in human thyroid tumours. Horm Metab Res 2010; 42: 237-240
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Atkinson H, England JA, Rafferty A et al. Somatostatin receptor expression in thyroid disease. Int J Exp Pathol 2013; 94: 226-229
    CrossrefPubMedGoogle Scholar
  • 29 Schulz S, Schulz St, Schmitt J et al. Immunocytochemical detection of somatostatin receptors SST1, SST2A and SST3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 1998; 4: 2047-2052
    PubMedGoogle Scholar
  • 30 Pisarek H, Pawlikowski M, Kunert-Radek J et al. SSTR 1 and SSTR 5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia Histochem Cytobiol 2010; 48: 142-147
    PubMedGoogle Scholar
  • 31 Pisarek H, Krupiński R, Kubiak R et al. The different expression of somatostatin receptor subtypes – related genes and proteins in non-functioning and functioning adrenal cortex adenomas. Mol Med Reports 2011; 4: 963-969
    PubMedGoogle Scholar
  • 32 Robbins RJ, Hill RH, Wang W et al. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 2000; 10: 177-183
    CrossrefPubMedGoogle Scholar
  • 33 Stokkel MP, Verkooijen RB, Bouwsma H et al. Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer. Nucl Med Commun 2004; 25: 683-690
    CrossrefPubMedGoogle Scholar
  • 34 Teunissen JJ, Kwekkeboom DJ, Kooij PP et al. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. J Nucl Med 2005; 46 (Suppl. 01) 107S-114S
    PubMedGoogle Scholar
  • 35 Budiawan H, Salavati A, Kulkarni H et al. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using 90Yttrium and 177Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging 2014; 4: 39-52
    PubMedGoogle Scholar
  • 36 Hoelting T, Duh QY, Clark OH et al. Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. J Clin Endocrinol Metab 1996; 81: 2638-2641
    PubMedGoogle Scholar
  • 37 Gorges R, Kahaly G, Muller-Brand J et al. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001; 11: 647-659
    CrossrefPubMedGoogle Scholar
  • 38 Waldherr C, Schumacher T, Pless M et al. Radiopeptide transmitted internal irradiation of non iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun 2001; 22: 673-678
    CrossrefPubMedGoogle Scholar
  • 39 Kohlfuerst S, Igerc I, Gallowitsch HJ et al. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?. Thyroid 2006; 16: 1113-1119
    CrossrefPubMedGoogle Scholar
  • 40 Durán-Prado M, Saveanu A, Luque RM et al. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab 2010; 95: 2497-2502
    Google Scholar
  • 41 Duran-Prado M, Gahete MD, Hergueta-Redondo M. The new truncated somatostatin receptor variant sst5TMD4 is associated with poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene 2013; 31: 2049-2061
    PubMedGoogle Scholar
  • 42 Puig-Domingo M, Luque RM, Reverter JL et al. The truncated isoform of somatostatin receptor 5 (sst5TMD4) is associated with poorly differentiated thyroid cancer. PLOS ONE 2014; 9: 1-7
    PubMedGoogle Scholar
  • 43 Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005; 46 (Suppl. 01) 67S-75S
    PubMedGoogle Scholar